Protagenic Therapeutics Inc.

09/14/2021 | Press release | Archived content

Correspondence (Form CORRESP)

Protagenic Therapeutics, Inc.

149 Fifth Avenue

New York, NY 10010

September 14, 2021

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Re:

Protagenic Therapeutics, Inc.

Registration Statement on Form S-3/A

Filed September 10, 2021

File No. 333-258825

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933 and on behalf of Protagenic Therapeutics, Inc. (the "Company"), the undersigned hereby requests that the Company's Registration Statement on Form S-3/A (File No. 333-258825) filed with the U.S. Securities and Exchange Commission (the "Commission") on September 10, 2021 (the "Registration Statement"), be declared effective on September 17, 2021, at 8:00 a.m., Eastern Standard Time, or as soon as practicable thereafter.

Very truly yours,
PROTAGENIC THERAPEUTICS, INC.
By: /s/ Alexander K. Arrow

Alexander K. Arrow

Chief Financial Officer

cc:

Dean Colucci, Duane Morris LLP